Cannabinoids
Two compounds that target the endocannabinoid system are currently in development to treat scleroderma – and they’re already in clinical trials. Pharmaceutical researchers have their sights set on developing a drug that bypasses CB1 while boosting CB2. Referred to as a “selective CB2 agonist,” such a compound would appear to have potential as a treatment […]
715
Like
Save
Your Premier Zero Free THC CBD Oil
){kind=link}